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Abstract
Background Capability well-being captures well-being based on people’s ability to do the things they value in life. So far, 
no capability well-being measures have been validated in dermatological patients.
Objectives To validate the adult version of the ICEpop CAPability measure (ICECAP-A) in patients with dermatological 
conditions. We aimed to test floor and ceiling effects, structural, convergent and known-group validity, and measurement 
invariance.
Methods In 2020, an online, cross-sectional survey was carried out in Hungary. Respondents with self-reported physician-
diagnosed dermatological conditions completed the ICECAP-A, Satisfaction with Life Scale (SWLS), WHO-5 Well-Being 
Index and two dermatology-specific measures, Dermatology Life Quality Index (DLQI) and Skindex-16.
Results 618 respondents (mean age 51 years) self-reported a physician-diagnosed dermatological condition, with warts, 
eczema, onychomycosis, acne and psoriasis being the most common. ICECAP-A performed well with no floor and mild 
ceiling effects. The violation of local independence assumption was found between the attributes of ‘attachment’ and ‘enjoy-
ment’. ICECAP-A index scores correlated strongly with SWLS and WHO-5 (rs = 0.597–0.644) and weakly with DLQI and 
Skindex-16 (rs = − 0.233 to − 0.292). ICECAP-A was able to distinguish between subsets of patients defined by education 
and income level, marital, employment and health status. Multigroup confirmatory factor analysis indicated measurement 
invariance across most of these subgroups.
Conclusions This is the first study to validate a capability well-being measure in patients with dermatological conditions. 
The ICECAP-A was found to be a valid tool to assess capability well-being in dermatological patients. Future work is rec-
ommended to test measurement properties of ICECAP-A in chronic inflammatory skin conditions.
Keywords Capability · Well-being · Quality of life · ICECAP · DLQI · Skindex-16
Introduction
Dermatological conditions are estimated to contribute to 
approximately 2% to the global burden of disease expressed 
in disability-adjusted life years, with dermatitis, including 
atopic, contact and seborrheic dermatitis, acne vulgaris, 
urticaria, psoriasis, viral and fungal skin diseases being 
responsible for the largest burden [1]. The adverse effect 
of skin diseases on patients’ health-related quality of life 
(HRQoL) is well-documented [2, 3]. A variety of disease-
specific (e.g. Psoriasis Disability Index, Quality of Life 
Index for Atopic Dermatitis), skin-specific (e.g. Dermatol-
ogy Life Quality Index, Skindex instrument family) and 
generic instruments (e.g. EQ-5D, Short-form 36) are used 
to assess HRQoL in dermatological patients [4]. In addi-
tion to HRQoL impact, many dermatological conditions 
have potential well-being implications for patients. In most 
societies, attractive and healthy appearance has a particu-
lar importance; thus, visible disorders of the skin, hair and 
nails may create a considerable psychological and social bur-
den that extends beyond health [5]. For example, patients 
with chronic skin diseases often report to experience lower 
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autonomy, personal growth, life satisfaction, happiness and 
purpose in life [6, 7].
HRQoL measures may not be able to capture the well-
being burden of living with a dermatological disease. 
Relatively few studies have so far examined the subjective 
well-being of dermatological patients [7–10], and none of 
them have investigated capability well-being. The capability 
approach, drawing on the work of Nobel Laureate econo-
mist Amartya Sen, addresses well-being in terms of people’s 
capabilities that reflect what people are able to do rather 
than what they actually do (i.e. functioning) [11]. So far, 
14 different capability-based well-being questionnaires have 
been developed for use in healthcare, such as the ICEpop 
CAPability Measure (ICECAP), Adult Social Care Out-
come Toolkit (ASCOT) and Oxford Capability question-
naire-Mental Health (OxCAP-MH) [12, 13]. Over the past 
decade, these questionnaires have been gaining increasing 
interest, especially because they may expand the evaluative 
space in health economic evaluations by allowing to value 
non-health attributes [12, 13]. In some countries, such as 
the UK and the Netherlands, health technology assessment 
bodies recommend the inclusion of capability outcomes 
in the assessment of health interventions and programmes 
where the intended benefits from interventions are associ-
ated with non-health-related effects (e.g. social or long-term 
care) [14, 15].
The ICECAP instruments are among the most frequently 
used capability well-being measures [13]. Previous studies 
have validated the adult (ICECAP-A) and elderly (ICECAP-
O) versions in several mental illnesses, including depres-
sion and drug addiction [16–18]; however, little empirical 
evidence is available on their measurement properties in the 
context of physical problems [19–22]. So far, the ICECAP 
measures or other capability-based well-being measures 
have not been validated in patients with dermatological 
conditions.
The objective of this study is to validate the ICECAP-A 
questionnaire in patients with dermatological conditions. We 
aim to test floor and ceiling effects, structural, convergent 




The study received ethics approval from the Research Eth-
ics Committee of the Medical Research Council in Hungary 
(Reference No. 3857-4/2019/EKU). In February 2020, an 
internet-based cross-sectional survey was carried out among 
the general population aged 18 years or over in Hungary. The 
survey population was recruited from members of an online 
panel by a survey company using non-probability quota sam-
pling. The online panel had over 150 thousand members who 
had voluntarily registered to complete surveys in return for 
earning survey points that could be later redeemed to various 
rewards (e.g. gift card, prizes). We aimed for representative-
ness of the Hungarian general public with respect to age, 
sex, education, place of living and region. Informed con-
sent was obtained from each respondent at the beginning of 
the survey. We followed the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) checklist 
for observational studies [23].
Questionnaire
A self-administered questionnaire was developed for the 
survey that recorded information about the presence of der-
matological conditions, sociodemographic characteristics, 
health status, HRQoL and well-being. General health status 
was measured in two separate questions. First, we used a 
0–100 horizontal VAS, with 0 being the ‘worst imaginable 
health’ and 100 being the ‘best imaginable health’. This scale 
is widely used to measure health status and demonstrated a 
good validity and excellent reliability [24]. Secondly, we 
asked respondents to rate their overall health as very good, 
good, fair, bad or very bad.
Respondents were queried about the presence of any der-
matological conditions in two steps. In the first step, they 
were asked to indicate if they had any dermatological condi-
tion at the time of the survey. For this question, a predefined 
list of ten dermatological disease categories (acne, basal cell 
carcinoma, eczema, herpes zoster, onychomycosis, psoria-
sis, rosacea, tinea pedis, urticaria and warts) and an ‘Other’ 
response option with an open-ended text box were provided 
to the respondents. In the second step, subjects that self-
reported any dermatological condition were asked to mark 
those conditions that were diagnosed by a physician. There 
was no missing data in this survey, as participants could 




ICECAP-A is a measure of capability well-being consist-
ing of the following five attributes: stability (an ability 
to feel settled and secure), attachment (an ability to have 
love, friendship and support), autonomy (an ability to 
be independent), achievement (an ability to achieve and 
progress in life) and enjoyment (an ability to experience 
enjoyment and pleasure) [25]. The Hungarian version of 
ICECAP-A has earlier been validated in a general popula-
tion sample [26]. We used a value set based on general 
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population preferences in the UK to compute ICECAP-A 
index scores [27]. These values are anchored on a zero (no 
capability on any attribute) to one (full capability on all 
attributes) scale.
Dermatology Life Quality Index (DLQI)
DLQI is a skin-specific HRQoL questionnaire consisting of 
10 items [28]. It aims to capture the impact of dermato-
logical conditions on the patients’ life over the last week. 
Each item has four or five possible response options that 
are scored from 0 (‘not at all’ or ‘not relevant’) to 3 (‘very 
much’). The scores of individual items are summed to gener-
ate a total DLQI score that ranges between 0 (no impact on 
HRQoL) and 30 (maximum HRQoL impact).
Skindex‑16
Similarly to the DLQI, Skindex-16 is also a skin-specific 
HRQoL measure with a one-week recall period [29]. It has 
16 individual items that are scored on a continuous bipolar 
scale with seven boxes anchored by the words ‘never both-
ered’ (= 0) and ‘always bothered’ (= 6). Responses to the 
items of Skindex-16 are categorised into three subscales: 
symptoms, emotions and functioning. Subscale scores are 
normalized to a 0–100 scale, where higher scores indicate 
worse HRQoL.
Well‑being, life satisfaction and happiness
The 5-item World Health Organization Well-Being Index 
(WHO-5) was administered to measure subjective well-
being over the last two weeks [30, 31]. It asks respondents 
to rate five positively phrased statements on a 0 (none of 
the time) to 5 (all of the time) scale, so that the final score 
ranges between 0 and 25. However, this is conventionally 
transformed to a 0–100 scale, where higher values indicate 
greater level of well-being. The Satisfaction with Life Scale 
(SWLS) was used to assess cognitive judgements of one’s 
life satisfaction [32]. Respondents were asked to indicate 
their degree of agreement on five items using a seven-point 
agreement scale with responses ranging from 1 (strongly 
disagree) to 7 (strongly agree). Total scores for this scale 
range from 5 to 35 with higher scores suggesting a higher 
life satisfaction. Furthermore, respondents rated their level 
of satisfaction with life (SWL) on an 11-point numeric rating 
scale with endpoints of ‘not satisfied at all’ (= 0) and ‘com-
pletely satisfied’ (= 10). A similar numeric scale was used 
to assess happiness with endpoints of ‘completely unhappy’ 
(= 0) and ‘completely happy’ (= 10).
Statistical analyses
Most of our analyses concerned with measurement proper-
ties that are relevant in the context of a measure to be used 
in economic evaluation [33]. These included floor and ceil-
ing effects, structural, convergent and known-group validity 
and measurement invariance. Most of these measurement 
properties have been tested in previous ICECAP-A and ICE-
CAP-O validation studies in general population and patient 
samples [16, 17].
Floor and ceiling effects
Descriptive statistics were used to provide an overview of 
the study population. Floor and ceiling effects were consid-
ered present if more than 15% of the respondents scored the 
worst and best capability level for attributes, or zero or one 
on ICECAP-A index, respectively [34].
Structural validity
Confirmatory factor analysis was carried out to confirm the 
factor structure of ICECAP-A. Model fit was tested using 
multiple criteria: χ2-statistic, comparative fit index (CFI), 
root-mean-square error of approximation (RMSEA) and 
Tucker-Lewis index (TLI) with values of a p < 0.05 for the 
χ2-statistic, CFI ≥ 0.90, RMSEA ≤ 0.08, CFI and TLI ≥ 0.95 
as an indication of good fit [35].
Convergent validity
We tested convergent validity for each ICECAP-A attrib-
ute as well as the index scores by using Spearman’s rank-
order correlations. Correlation coefficients (rs) were con-
sidered very weak if < 0.20, weak if 0.20–0.39, moderate if 
0.40–0.59 and strong if ≥ 0.60 [36]. We expected strong cor-
relations with life satisfaction measures (SWLS and SWL) 
[37], moderate correlations with health status VAS [13, 20, 
22, 37] and subjective well-being as assessed by the WHO-5 
[26] and happiness [38], and weak correlations with skin-
specific HRQoL measures (DLQI and Skindex-16) [22].
Known‑group validity
Known-group validity was assessed by examining the extent 
to which the ICECAP-A was able to distinguish between 
groups of respondents differing in a characteristic that 
was likely to be associated with capability well-being. We 
hypothesized no associations between capability scores and 
age or sex, and positive associations of capabilities with bet-
ter self-perceived health status, being more educated, being 
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married or living in a domestic partnership, being employed 
and having a higher income level [22, 26, 37, 38]. The differ-
ences in median ICECAP-A scores across groups were tested 
by Mann–Whitney U or Kruskal Wallis H test.
Measurement invariance
Measurement invariance of the ICECAP-A across different 
subgroups [sex, age (< 65 years vs. ≥ 65 years), level of edu-
cation, marital status, income and DLQI score (DLQI ≤ 10 
vs. DLQI > 10)] was evaluated using multigroup confirma-
tory factor analysis [39]. DLQI score was split at ten points 
as DLQI > 10 is considered a ‘very large impact’ of the der-
matological condition on patients’ lives [40]. A sequence of 
configural (i.e. same pattern of factors), metric (i.e. same 
pattern of factors and loadings) and scalar (i.e. same pattern 
of factors, loadings and item thresholds) models were tested 
for each variable. We first examined the fit of the configural 
model. For the assessment of model fit, χ2-statistic, TLI, 
CFI and RMSEA were used. We compared the fit of the 
unconstrained configural model to the metric model, and 
then, the metric model to the most constrained scalar model. 
A decrease in CFI ≤ 0.01 was considered as an evidence for 
invariance [41]. All the statistical tests were two-sided, and 
p < 0.05 was considered statistically significant. We used 




A total of 3873 people opened the questionnaire, 60 indi-
viduals did not consent to the study, 1354 did not finish it 
and 458 did not meet the quotas, resulting in a final sample 
of 2001 respondents (Fig. 1). Of the 2001 respondents, 618 
individuals self-reported a dermatological condition diag-
nosed by a physician, and thus, formed the analytical sam-
ple for this study. The majority of the sample was female 
(57.9%), and the mean age was 50.5 ± 16.9 years (Table 1). 
The most common dermatological conditions in the sam-
ple were warts (23.1%), eczema (22.7%), onychomycosis 
(18.3%), acne (13.4%), psoriasis (13.3%), tinea pedis (7.4%), 
basal cell carcinoma (5.0%), rosacea (5.0%), urticaria 
(3.6%), herpes zoster (1.6%) and other (16.5%) (the pres-
ence of multiple diseases in one individual was possible). 
Responses for the open-ended ‘other dermatological condi-
tion’ category are presented in Online resource 1.
Fig. 1  Study flowchart
Quality of Life Research 
1 3
Table 1  Characteristics of the 
study population and descriptive 
statistics of ICECAP-A index 
scores
IQR interquartile range, SD standard deviation
a Mann–Whitney U test or Kruskal Wallis H test
Variables n (%) ICECAP-A index score
Mean (SD) Median (IQR) p-value a
Total sample 618 (100%) 0.69 (0.20) 0.72 (0.26) –
Sex
 Female 358 (57.9%) 0.70 (0.20) 0.76 (0.25) 0.191
 Male 260 (42.1%) 0.68 (0.20) 0.70 (0.27)
Age groups (years)
 18–24 42 (6.8%) 0.73 (0.16) 0.76 (0.23) 0.166
 25–34 92 (14.9%) 0.71 (0.18) 0.70 (0.26)
 35–44 106 (17.2%) 0.65 (0.23) 0.70 (0.34)
 45–54 106 (17.2%) 0.70 (0.18) 0.75 (0.25)
 55–64 89 (14.4%) 0.65 (0.23) 0.69 (0.34)
 65–74 159 (25.7%) 0.72 (0.17) 0.76 (0.27)
 75 + 24 (3.9%) 0.72 (0.22) 0.77 (0.26)
Highest level of education
 Primary 31 (5%) 0.61 (0.20) 0.66 (0.33)  < 0.001
 Secondary 462 (74.8%) 0.68 (0.20) 0.69 (0.30)
 Tertiary 125 (20.2%) 0.77 (0.16) 0.83 (0.12)
Marital status
 Married 291 (47.1%) 0.72 (0.19) 0.76 (0.27) 0.019
 Divorced 63 (10.2%) 0.63 (0.23) 0.64 (0.41)
 Widowed 40 (6.5%) 0.68 (0.24) 0.78 (0.35)
 Domestic partnership 130 (21%) 0.70 (0.18) 0.71 (0.24)
 Other 94 (15.2%) 0.66 (0.20) 0.69 (0.32)
Employment
 Full-time 249 (40.3%) 0.72 (0.18) 0.76 (0.27)  < 0.001
 Part-time 30 (4.9%) 0.66 (0.18) 0.68 (0.25)
 Retired 190 (30.7%) 0.72 (0.19) 0.76 (0.27)
 Disability pensioner 45 (7.3%) 0.65 (0.20) 0.69 (0.25)
 Student 33 (5.3%) 0.71 (0.17) 0.76 (0.22)
 Unemployed 31 (5%) 0.50 (0.25) 0.53 (0.36)
 Homemaker/housewife 23 (3.7%) 0.62 (0.23) 0.64 (0.35)
 Other 17 (2.8%) 0.66 (0.20) 0.70 (0.41)
Net monthly household income per capita
 HUF 0–100,623 111 (18%) 0.62 (0.23) 0.67 (0.36)  < 0.001
 HUF 100,624–137,500 121 (19.6%) 0.67 (0.21) 0.69 (0.30)
 HUF 137,501–194,454 133 (21.5%) 0.68 (0.18) 0.69 (0.24)
 HUF 194,455–265,165 78 (12.6%) 0.76 (0.17) 0.85 (0.26)
 HUF 265,166 + 91 (14.7%) 0.78 (0.16) 0.82 (0.21)
 Don’t know/refused to answer 84 (13.6%) 0.69 (0.19) 0.70 (0.27)
Self-perceived health status
 Very good 33 (5.3%) 0.83 (0.14) 0.85 (0.21)  < 0.001
 Good 198 (32%) 0.79 (0.14) 0.85 (0.19)
 Fair 264 (42.7%) 0.68 (0.19) 0.69 (0.26)
 Bad 107 (17.3%) 0.56 (0.19) 0.55 (0.28)
 Very bad 16 (2.6%) 0.41 (0.22) 0.44 (0.34)
Health-related quality of life (Dermatology 
Life Quality Index)
 DLQI ≤ 10 552 (89.3%) 0.70 (0.19) 0.75 (0.25) 0.002
 DLQI > 10 66 (10.7%) 0.61 (0.23) 0.62 (0.37)
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Health status, HRQoL and well‑being
Patients assessed their general health status to a mean of 
66.54 ± 23.35 using a 0–100 VAS, ranging from 51.42 in 
herpes zoster to 68.75 in acne (Fig. 2). The proportion of 
patients with ‘very good’ or ‘good’ self-reported health 
status was 37.5%, while 42.7% indicated ‘fair’ and 19.9% 
‘bad’ or ‘very bad’. The mean DLQI score in the sample 
was 3.76 ± 5.03 (Table 2). More problems were reported 
on the emotions subscale of Skindex-16 (35.92 ± 30.38) 
compared with symptoms (29.98 ± 28.62) and functioning 
(22.15 ± 28.31). The mean SWLS, SWL, WHO-5 and hap-
piness scores were 20.08 ± 6.75, 5.93 ± 2.39, 49.69 ± 19.94 
and 6.11 ± 2.45, respectively. 
Fig. 2  Mean ICECAP-A index and health status VAS scores. ICECAP-A ICEpop CAPability measure for adults, VAS visual analogue scale
Table 2  Descriptive statistics of 
the outcome measures
For DLQI and Skindex, higher scores represent worse outcomes, for all other measures higher scores indi-
cate better outcomes
DLQI Dermatology Life Quality Index, ICECAP-A ICEpop CAPability measure for adults, SWLS Satisfac-
tion with Life Scale, SWL Satisfaction with Life visual analogue scale, VAS visual analogue scale, WHO-5 
5-item World Health Organisation Well-Being Index
Mean SD Median Q1–Q3 Min Max
ICECAP-A index score (0–1) 0.69 0.20 0.72 0.59–0.85 0.00 1.00
Health status VAS (0–100) 66.54 23.35 71.00 50.00–85.00 0.00 100.00
DLQI (0–30) 3.76 5.03 2.00 0.00–5.56 0.00 29.00
Skindex-16 symptoms (0–100) 29.98 28.62 25.00 4.17–50.00 0.00 100.00
Skindex-16 emotions (0–100) 35.92 30.38 30.95 9.52–57.14 0.00 100.00
Skindex-16 functioning (0–100) 22.15 28.31 6.67 0.00–40.00 0.00 100.00
WHO-5 (0–100) 49.69 19.94 52.00 36.00–64.00 0.00 100.00
SWLS (5–35) 20.08 6.75 20.00 15.00–25.00 5.00 35.00
SWL (0–10) 5.93 2.39 6.00 5.00–8.00 0.00 10.00
Happiness (0–10) 6.11 2.45 7.00 5.00–8.00 0.00 10.00
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Capability well‑being outcomes
Approximately half of patients recorded responses on the 
two lowest levels of capability for stability (52.1%) and 
achievement (49.7%) of ICECAP-A (Fig. 3). The largest 
proportion of responses in the lowest level was observed for 
stability (‘I am unable to feel settled and secure in any areas 
of my life’, 10.0%). Over two-thirds of patients reported no 
or mild limitations (highest two levels on ICECAP-A) in 
their capabilities for the attachment (i.e. love friendship, 
support), autonomy (i.e. being independent) and enjoyment 
(i.e. enjoyment and pleasure) attributes. The mean ICECAP-
A index score was 0.69 ± 0.20, ranging from 0.61 in herpes 
zoster to 0.76 in basal cell carcinoma (Fig. 2). The impact 
of various dermatological conditions on health and capa-
bility differed; certain conditions (e.g. herpes zoster) had a 
large effect on both health and capabilities, while others (e.g. 
acne, eczema) mostly affected capabilities. Mean ICECAP-
A index scores of patients with a DLQI ≤ 10 and DLQI > 10 
were 0.70 ± 0.19 and 0.61 ± 0.23, respectively (p = 0.002).
Measurement properties of ICECAP‑A
Floor and ceiling effects
No floor effects were detected for any of the five attributes. 
Ceiling effects were apparent for the attributes of attachment 
(23.0%), autonomy (17.6%) and enjoyment (18.6%) (Fig. 3). 
Five (0.8%) patients reported full capability and four (0.7%) 
patients were in ‘no capability’; thus, there were no ceiling 
or floor effects for the index scores.
Structural validity
A one-factor model was established in confirmatory fac-
tor analysis with the following goodness-of-fit indices: 
χ2 = 35.55 (p < 0.001), RMSEA = 0.100, TLI = 0.935 and 
CFI = 0.968. A covariance between the error terms (i.e. local 
dependency) was identified between the attributes of attach-
ment and enjoyment that improved the model fit [χ2 = 10.18 
(p = 0.037), RMSEA = 0.050, TLI = 0.984 and CFI = 0.993] 
(Fig. 4).
Convergent validity
Most hypotheses regarding convergent validity were 
met. The ICECAP-A index showed a strong correla-
tion with SWLS, SWL, WHO-5 and happiness scores 
(rs = 0.597–0.689) (Table 3). A moderate or strong cor-
relation was found between these four outcomes and all 
ICECAP-A attributes with the exception of autonomy 
(rs = 0.281–0.607). General health status VAS exhibited a 
moderate correlation with the ICECAP-A index and weak 
correlation with the five attributes (rs = 0.233–0.449). DLQI 
and the three Skindex-16 subscales were weakly or very 
weakly correlated with all five ICECAP-A attributes and 
index score (rs = − 0.123 to − 0.292).
Known‑group validity
All our hypotheses with respect to validity between known 
groups of patients were confirmed. Patients with worse self-
perceived health status, lower level of education, those not 
being married or living in domestic partnership, unemployed 
or with lower income were associated with significantly 
Fig. 3  Distribution of responses on the five attributes of ICECAP-A. ICECAP-A ICEpop CAPability measure for adults. Percentages may not 
add up 100% due to reounding
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lower levels of capability-well-being (Table 1). As expected, 
there were no significant associations between age or sex and 
ICECAP-A index scores.
Measurement invariance
Configural and metric measurement invariance were sup-
ported (ΔCFI ≤ 0.01) across all subgroups of patients 
defined by sex, age, level of education, being married/living 
in a domestic partnership, income, self-perceived health sta-
tus and HRQoL as assessed by the DLQI (Table 4). The sca-
lar invariance model demonstrated a slight deterioration in 
model fit, but only for age, marital status and DLQI groups.
Discussion
In prior studies, patients with chronic skin diseases, such as 
psoriasis, pemphigus and morphea, were more likely to be 
associated with decreased subjective well-being, happiness 
and life satisfaction [7–9, 42–44]. Yet this is the first study 
to validate a capability well-being instrument in dermato-
logical patients. Corroborating with previous research on 
the validity of ICECAP-A in other clinical and population-
based studies [16], our findings provide mostly favourable 
evidence on the psychometric properties of ICECAP-A 
in a dermatological patient population, including no floor 
effect, good convergent and known-group validity and estab-
lished metric and configural invariance across subgroups of 
Fig. 4  Confirmatory factor 
analysis of the structure of 
ICECAP-A. ICECAP-A ICEpop 
CAPability measure for adults
Table 3  Convergent validity of ICECAP-A attributes and index scores (Spearman’s correlations)
p < 0.05 for all correlation coefficients
For DLQI and Skindex, higher scores represent worse outcomes, for all other measures higher scores indicate better outcomes
DLQI Dermatology Life Quality Index, ICECAP-A ICEpop CAPability measure for adults, SWLS Satisfaction with Life Scale, SWL Satisfaction 
with Life visual analogue scale, VAS visual analogue scale, WHO-5 5-item World Health Organisation Well-Being Index
Outcome measures ICECAP-A
Stability Attachment Autonomy Achievement Enjoyment Index score
Health status VAS (0–100) 0.380 0.334 0.233 0.367 0.339 0.449
DLQI (0–30) − 0.236 − 0.200 − 0.201 − 0.182 − 0.220 − 0.271
Skindex-16 symptoms (0–100) − 0.215 − 0.184 − 0.144 − 0.123 − 0.194 − 0.233
Skindex-16 emotions (0–100) − 0.221 − 0.206 − 0.146 − 0.148 − 0.203 − 0.247
Skindex-16 functioning (0–100) − 0.242 − 0.244 − 0.167 − 0.187 − 0.259 − 0.292
WHO-5 (0–100) 0.559 0.417 0.351 0.518 0.537 0.644
SWLS (5–35) 0.565 0.449 0.281 0.451 0.453 0.597
SWL (0–10) 0.607 0.533 0.339 0.524 0.538 0.689
Happiness (0–10) 0.560 0.574 0.305 0.490 0.586 0.685
Quality of Life Research 
1 3
patients. However, a mild ceiling effect was present for three 
attributes, and a local dependence was identified between 
two of the five attributes.
The sample used for this study was large and heterogene-
ous representing the most common dermatological condi-
tions in the population, such as warts, eczema, onychomy-
cosis, acne, psoriasis and tinea pedis, among others. There 
are no data available on the precise prevalence of most der-
matological conditions in Hungary. Few existing prevalence 
estimates from Hungary or the Central and Eastern Euro-
pean region include adult psoriasis (Central Europe: range 
0.62–5.32%) and atopic eczema (5%) [45, 46]. In our study, 
the number of patients with psoriasis and eczema (a wider 
category than atopic eczema) in the total sample (n = 2001) 
was 82 (4.1%) and 141 (7.0%), respectively, suggesting a 
good overall representativeness.
Approximately half of the sample reported severe limi-
tations in their stability (feeling settled and secure) and 
achievement and progress. Mean ICECAP-A index (0.69) 
was found to be considerably lower than previously reported 
in other clinical groups (e.g. spinal cord injury 0.76 [37], 
arthritis 0.81 [47], asthma 0.84 [47], lower urinary tract 
symptoms 0.85 [22], knee pain 0.89 [21]); but somewhat 
higher than in patients with opiate dependence (0.66) [48] 
or depression (0.64) [18]. Moreover, < 1% experienced full 
capability with regard to all five attributes of ICECAP-A 
that was 3% and 12% in patients with spinal cord injury 
and lower urinary tract symptoms, respectively [22, 37]. 
However, comparison of these scores might be limited by 
the different language versions of ICECAP-A used in the 
studies and possible cross-cultural and condition-specific 
differences in the interpretation of the attributes.
Attributes of ICECAP-A were developed to capture five 
independent and distinct concepts, three of which, ‘attach-
ment’, ‘autonomy’ and ‘enjoyment’ were aimed to be close 
equivalents to ‘emotions’, ‘control’ and ‘play’ from Nuss-
baum’s list of central human capabilities [25]. Notwithstand-
ing, we found the violation of local independence between 
the attributes of attachment (an ability to have love, friend-
ship and support) and enjoyment (ability to experience 
enjoyment and pleasure) suggesting an overlap in the content 
of the attributes. This is not surprising as during the devel-
opment of the ICECAP-A, the attribute of attachment was 
reported to be strongly related to the interactions with other 
people, including partner, close family and good friends, 
Table 4  Measurement 
invariance (multigroup CFA)
Groups: sex: female vs. male; age: < 65 years vs. ≥ 65 years; marital status: married/living in a domestic 
partnership vs. other; income: quintile groups; education: primary/secondary vs. tertiary; self-perceived 
health status: very good/good vs. fair/bad/very bad; DLQI groups: DLQI ≤ 10 vs. DLQI > 10
Bolded values indicate the lack of measurement invariance
df degrees of freedom, CFA confirmatory factor analysis, CFI comparative fit index, RMSEA root-mean-
square error of approximation, TLI Tucker–Lewis Index
Group Model df χ2 p-value TLI RMSEA CFI ΔCFI
Sex Configural 8 13.178 0.106 0.986 0.032 0.995 –
Metric 12 16.824 0.156 0.991 0.026 0.995 0.000
Scalar 17 20.736 0.238 0.995 0.019 0.996 0.001
Age Configural 8 16.227 0.039 0.978 0.041 0.991 –
Metric 12 17.717 0.125 0.990 0.028 0.994 0.003
Scalar 17 43.217  < 0.001 0.967 0.050 0.972 0.022
Education Configural 28 75.075  < 0.001 0.944 0.052 0.948 –
Metric 32 83.280  < 0.001 0.947 0.051 0.943 0.005
Scalar 37 86.521  < 0.001 0.955 0.047 0.945 0.002
Marital status Configural 8 11.943 0.154 0.989 0.028 0.996 –
Metric 12 14.228 0.286 0.996 0.017 0.998 0.002
Scalar 17 48.516  < 0.001 0.960 0.055 0.966 0.032
Income Configural 68 118.299  < 0.001 0.950 0.037 0.932 –
Metric 72 119.750  < 0.001 0.955 0.035 0.935 0.003
Scalar 77 125.028  < 0.001 0.958 0.034 0.935 0.000
Self-perceived 
health status
Configural 28 52.423 0.003 0.972 0.038 0.974 –
Metric 32 55.283 0.006 0.976 0.034 0.975 0.001
Scalar 37 59.238 0.012 0.981 0.031 0.976 0.001
DLQI Configural 8 17.711 0.024 0.974 0.044 0.990 –
Metric 12 24.706 0.016 0.977 0.041 0.986 0.004
Scalar 17 43.692  < 0.001 0.967 0.050 0.972 0.014
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and being around other people may also be a major source 
of enjoyment and pleasure in life [25, 38].
The ICECAP-A was able to differentiate between 6 of 8 
predefined known groups of patients. Higher education and 
income level, being married or living in a domestic partner-
ship, and better self-perceived general health status or skin-
specific HRQoL were associated with higher capability lev-
els, while unemployed patients scored lower on ICECAP-A. 
The positive associations between higher ICECAP-A scores 
and marital status, labour force participation and better gen-
eral health status have earlier been confirmed in patients with 
type 2 diabetes and spinal cord injury [19, 37]. Evidence is 
less conclusive with regard to the association of age and 
ICECAP-A scores. Three earlier studies among members 
of the general population and female patients with urinary 
incontinence reported the lack of association between age 
and ICECAP-A scores [22, 25, 26], whereas another study 
identified a clear trend towards lower ICECAP-A scores with 
older age in patients with type 2 diabetes [19].
The measurement equivalence found in this study high-
lights that ICECAP-A scores can be reliably compared 
across most known groups of patients. However, scalar 
equivalence was not confirmed for all subgroups suggesting 
that certain groups (e.g. being married/living in a domestic 
partnership or not, DLQI ≤ 10 and DLQI > 10) tend to inter-
pret the attributes of the ICECAP-A in a different way, and 
differences in scores between these groups are suggested to 
be treated with caution.
The weak correlation of the ICECAP-A with DLQI and 
Skindex-16 confirmed that capability wellbeing is a dif-
ferent, but complement construct to HRQoL. It has been 
increasingly argued to look at outcomes other than health 
ones, including subjective well-being and capabilities [11, 
49, 50]. In addition to health gains, health interventions 
may offer capability gains too that can represent additional 
treatment benefits. Health economists and policymakers 
in healthcare may also see this compelling as adopting the 
capability wellbeing perspective has already demonstrated 
to result in different cost-effectiveness estimates, and thus, 
treatment recommendations for certain health interven-
tions [51, 52]. The National Institute for Health and Care 
Excellence (NICE) in the UK has already recommended the 
ICECAP-A and its elderly version, the ICECAP-O question-
naires in its reference case for evaluating social care inter-
ventions [15].
Strengths of this study are the large and heterogene-
ous patient sample and the survey design that ensured a 
broad representation of the general population. A further 
strength is the use of validated skin-specific HRQoL meas-
ures, such as the DLQI and Skindex-16. To our knowledge, 
we are the first to test measurement invariance for the ICE-
CAP-A. There are some limitations that are worth noting. 
First, disadvantages of the online data collection, such as 
excluding people with no internet access should be consid-
ered. In Hungary among the population 16 years or older, 
the average internet penetration rate at the time of this 
survey was around 80% [53]. Thus, selection bias might 
have occurred, to some extent. Secondly, the study was 
based on self-reported information on diagnosis provided 
by patients that may be more prone to errors compared 
to data collection in clinical settings, whereby diagnosis 
is confirmed by physicians. Thirdly, the survey reached 
mostly less severe cases as 89.3% had a DLQI score 
of ≤ 10. Furthermore, we did not have any information on 
the treatment history of these patients. Several earlier stud-
ies from Hungary confirmed that successful treatment and 
management of skin diseases improve health-related qual-
ity of life and well-being of patients [9, 54–59]. Fourthly, 
in absence of a Hungarian value set for the ICECAP-A, 
our analyses relied on the ICECAP-A value set for the UK 
and not that of the Hungarian population, whose values 
may differ across attributes and levels. Finally, this study 
had a cross-sectional design that prevented the assessment 
of other measurement properties, such as test–retest reli-
ability and responsiveness.
In conclusion, the ICECAP-A was found to be a valid tool 
to measure capability well-being in a dermatological patient 
population. However, a local dependency was found between 
the attributes of ‘attachment’ and ‘enjoyment’ that war-
rants further investigation. Future studies are recommended 
to assess capability well-being and confirm measurement 
properties of the ICECAP-A in common chronic inflamma-
tory skin diseases, such as psoriasis, atopic dermatitis and 
acne. Further research steps also include the validation of the 
elderly version of ICECAP, the ICECAP-O in dermatologi-
cal patients as well as the validation of alternative capability 
measures in this patient population.
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